دورية أكاديمية
Favipiravir Efficacy And Safety For The Treatment Of Severe Coronavirus Disease 2019: A Retrospective Study.
| العنوان: | Favipiravir Efficacy And Safety For The Treatment Of Severe Coronavirus Disease 2019: A Retrospective Study. |
|---|---|
| المؤلفون: | Abdulrahman B; Pharmaceutical Care Department., Mady A; Intensive Care Department, King Saud Medical City, Riyadh, Saudi Arabia and Department of Anaesthesiology and Intensive Care, Tanta University Hospitals, Tanta, Egypt., Odat MA; Intensive Care Department, King Saud Medical City, Riyadh, Saudi Arabia., Tayar AA; Security Forces Hospital, Dammam, Saudi Arabia., Rana MA; Critical Care Medicine Bahria International Hospital Lahore, Pakistan., Alharthy A; Intensive Care Department, King Saud Medical City, Riyadh, Saudi Arabia., Alhazmi A; Department of Critical Care, Dr. Sulaiman Al-Habib Medical Group, Riyadh, Saudi Arabia., Abdelmoaty AS; Tropical Medicine Department, Ain Shams University, Cairo, Egypt., Hafeez MM; Expert Doctors PVT, Ltd, Lahore, Pakistan., Kuhail A; Intensive Care Department, King Saud Medical City, Riyadh, Saudi Arabia., Noor AM; Critical Care Department, Charing Cross Hospital, Imperial College, London., Haddad M; Intensive Care Department, King Saud Medical City, Riyadh, Saudi Arabia., Mady A; College of Medicine, AL Faisal University, Riyadh, Saudi Arabia., Ali N; Paediatric Department, Al-Basheer hospital, Amman, Jordan., Mhawish H; Critical Care Department, King Saud Medical City, Riyadh, Saudi Arabia., Aletreby W; Intensive Care Department, King Saud Medical City, Riyadh, Saudi Arabia. |
| المصدر: | Journal of Ayub Medical College, Abbottabad : JAMC [J Ayub Med Coll Abbottabad] 2022 Jul-Sep; Vol. 34 (3), pp. 397-402. |
| نوع المنشور: | Observational Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Ayub Medical College Country of Publication: Pakistan NLM ID: 8910750 Publication Model: Print Cited Medium: Internet ISSN: 1819-2718 (Electronic) Linking ISSN: 10259589 NLM ISO Abbreviation: J Ayub Med Coll Abbottabad Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Abbottabad : Ayub Medical College |
| مواضيع طبية MeSH: | COVID-19 Drug Treatment*, Humans ; SARS-CoV-2 ; Retrospective Studies ; Creatinine ; Treatment Outcome ; Bilirubin |
| مستخلص: | Background: Corona virus disease is caused by the enveloped, single stranded RNA virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) becoming the deadliest disease of the century. Its global outbreak has led researchers to develop drugs or vaccines to prevent the spread of the disease. Favipiravir is an approved orally administered antiviral drug that selectively inhibits RNA-dependent RNA polymerase, used off-label to treat COVID-19. Objectives: The purpose of this study was to assess the efficacy and safety of this drug for severe COVID-19 infection. Methods: This was an observational retrospective study, carried out at the ICU of King Saud Medical City (KSMC) from June 2020 to August 2020. Including a total of one thousand six hundred and ninety-nine patients (n=1699). Categorized into a treatment group (193 patients) who received Favipiravir along with standard care, and non-treatment group (1506 patients) who received standard care only. Results: ICU all-cause mortality was similar in both groups i.e., (Treated group 38.3% Vs Untreated group 39.4%, 95% CI of difference: -6.6% to +8.4%; p = 0.8). The subgroup analysis of survivors as compared to deceased in the treatment group showed that survivors had significantly lower age, international normalising ratio (INR), blood urea nitrogen (BUN), and creatinine. The mean ICU length of stay (LOS) was shorter for survivors compared to deceased (11.2± 8.03 Vs 16.7±9.8 days respectively), while hospital LOS was almost similar between the two groups. Advanced age (OR 1.03 [95% CI: 1.01-1.06]; p=0.004), higher INR and BUN were significantly associated with increased odds of mortality. Comparison of lab investigations at day 1 and day 10 in the treatment group (regardless of outcome) showed that there was a significant increase in Alanine transaminase (ALT), alkaline phosphatase (ALK), and Bilirubin, while an insignificant trend of increase in Aspartate transaminase (AST) and creatinine was recorded. Conclusions: In this study, Favipiravir showed better therapeutic responses in patients with severe COVID-19 infection, in terms of average duration of stay in the intensive care unit and was well tolerated in the younger age, but showed no mortality benefit. However, elevated levels of inflammatory markers, including increased ALT, AST, BUN, bilirubin, and creatinine, needs to be carefully examined. |
| فهرسة مساهمة: | Keywords: Covid-19; antiviral; Favipiravir; All-cause mortality; Outcomes; Severe disease |
| المشرفين على المادة: | EW5GL2X7E0 (favipiravir) AYI8EX34EU (Creatinine) RFM9X3LJ49 (Bilirubin) |
| تواريخ الأحداث: | Date Created: 20221115 Date Completed: 20221116 Latest Revision: 20221207 |
| رمز التحديث: | 20240628 |
| DOI: | 10.55519/JAMC-03-10305 |
| PMID: | 36377144 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1819-2718 |
|---|---|
| DOI: | 10.55519/JAMC-03-10305 |